<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Nuritas 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=39126></link><description><![CDATA[Nuritas 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 03 May 2026 01:06:34 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/11/12_3554238800_20211112113913_9672672040.gif]]></url></image><language>ko-KR</language><item><title><![CDATA[Nuritas™ Raises $45 Million To Scale Its Peptide Discovery Platform And Expand Globally]]></title><link>https://www.newswire.co.kr/newsRead.php?no=934292</link><description><![CDATA[DUBLIN--(Business Wire/Korea Newswire)--Nuritas, a biotechnology company revolutionizing the discovery and development of plant-based bioactive peptides, has closed a $45 million USD Series B funding round. The investment, led by Chicago-based Cleveland Avenue, LLC, includes Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund (ECBF), Singapore-based Vertex Holdings, Nu...]]></description><pubDate>Fri, 12 Nov 2021 13:20:00 +0900</pubDate></item><item><title><![CDATA[뉴리타스, 펩티드 발견 플랫폼 확장 및 세계 진출 위해 4500만달러 조달]]></title><link>https://www.newswire.co.kr/newsRead.php?no=934293</link><description><![CDATA[더블린--(Business Wire/뉴스와이어)--식물성 생리활성 펩타이드의 발견과 개발에 변혁을 일으키고 있는 생명공학 기업 뉴리타스(Nuritas)가 4500만달러 규모의 시리즈 B 펀딩 라운드를 마감했다.  시카고에 기반을 둔 클리블랜드 애비뉴(Cleveland Avenue, LLC)가 주도하는 이번 투자에는 그로스베너 위트시프 그룹(Grosvenor’s Wheatsheaf Group), ECBF(European Circular Bioeconomy Fund), 싱가포르에 기반을...]]></description><pubDate>Fri, 12 Nov 2021 13:20:00 +0900</pubDate></item></channel></rss>